Cytogenetics of extramedullary manifestations in multiple myeloma

British Journal of Haematology

Volumn 161, Issue 1, 2013, Pages 87-94

  Billecke, Lisa ^a   Murga Penas, Eva M ^a,g   May, Annette M ^b   Engelhardt, Monika ^b   Nagler, Arnon ^c   Leiba, Merav ^c   Schiby, Ginette ^c   Kröger, Nicolaus ^a   Zustin, Jozef ^a   Marx, Andreas ^a   Matschke, Jakob ^a   Tiemann, Markus ^d   Goekkurt, Eray ^e   Heidtmann, Hans Heinrich ^f   Vettorazzi, Eik ^a   Dierlamm, Judith ^a   Bokemeyer, Carsten ^a   Schilling, Georgia ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SHEBA MEDICAL CENTER   (Israel)

^d Institute of Haematopathology   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f StJoseph Hospital Bremerhaven   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CIg FISH; Cytogenetics; Extramedullary manifestations; Multiple myeloma; Paraffin embedded material

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE MARROW CELL; CANCER GROWTH; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; EXTRAMEDULLARY DISEASE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOW DRUG DOSE; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLASMACYTOMA; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE MYC; PLASMA CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84875054416     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12223     Document Type: Article

References (35)

1. Agresti, A. (2002) Categorial Data Analysis, 2nd edn. Wiley-Interscience, New York.
2. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S. & Bataille, R.; Intergroupe Francophone du Myélome (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
3. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome Genetic abnormalities and survival in multiple of the Intergroupe Francophone du Myélome. Blood, 109, 3489-3495.
4. Billecke, L., Murga Penas, E.M., May, A.M., Engelhardt, M., Nagler, A., Schiby, G., Kröger, N., Zustin, J., Marx, A., Matschke, J., Tiemann, M., Goekkurt, E., Bokemeyer, C. & Schilling, G. (2012) Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissues, and osteolyses of patients with multiple myeloma. Anticancer Research, 32, 2031-2034.
5. Bink, K., Haralambieva, E., Kremer, M., Ott, G., Beham-Schmid, C., de Leval, L., Peh, S.C., Laeng, H.R., Jütting, U., Hutzler, P., Quintanilla-Martinez, L. & Fend, F. (2008) Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica, 93, 623-626.
6. Bladé, J., Férnandez de Larrea, C.F., Rosinol, L., Cibeira, M.T., Jiménez, R. & Powles, R. (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology, 29, 3805-3812.
7. Chang, H., Sloan, S., Li, D. & Stewart, A.K. (2004) Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. British Journal of Haematology, 127, 280-284.
8. Chiecchio, L., Dagrada, G.P., Ibrahim, A.H., Dachs Cabanas, E., Protheroe, R.K.M., Stockley, D.M., Orchard, K.H., Cross, N.C., Harrison, C.J. & Ross, F.M.; UK Myeloma Forum. (2009) Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica, 94, 1708-1713.
9. Detweiler Short, K., Rajkumar, S.V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Kumar, S., Zeldenrust, S.R., Russell, S.J., Lust, J.A., Kyle, R.A., Greipp, P.R., Witzig, T.E. & Rajkumar, V. (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia, 25, 906-908.
10. Dierlamm, J., Schilling, G., Süßmilch, S., Seeger, D., Hinz, K., Murga Penas, E.M. & Hossfeld, D.K. (2001) Incidence and prognostic significance of deletions of tumor suppressor genes and aneuploidies in multiple myeloma: an interphase FISH study. European Journal of Cancer, 37(Suppl. 6), 96.
11. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
12. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, RA., Dewald, G.W., van Ness, B., van Wier, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
13. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarski, L.M., Shaughnessy, J.D. Jr, Stewart, A.K. & Avet-Loiseau, H. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research, 64, 1546-1558.
14. Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A.K., Morgan, G., van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., Kuehl, W.M., Liebisch, P., Davies, F., Chen-Kiang, S., Durie, B.G., Carrasco, R., Sezer, O., Reiman, T., Pilarski, L. & Avet-Loiseau, H. International Myeloma Working Group. (2009) Molecular classification of multiple myeloma: spotlight review. IMWG molecular classification of MM. Leukemia, 23, 2210-2221.
15. Galieni, P., Cavo, M., Pulsoni, A., Avvisati, G., Bigazzi, C., Neri, S., Caliceti, U., Benni, M., Ronconi, S. & Lauria, F. (2000) Clinical outcome of extramedullary plasmacytoma. Haematologica, 85, 47-51.
16. Gozzetti, A., Cerase, A., Lotti, F., Rossi, D., Palumbo, A., Petrucci, M.T., Patriarca, F., Nozzoli, C., Cavo, M., Offidani, M., Floridia, M., Berretta, S., Vallone, R., Musto, P. & Lauria, F. GIMEMA (Malattie, Ematologiche, Gruppo Italiano dell'Adulto) Myeloma Working Party, Marchini, E., Fabbri, A., Oliva, S., Zamagni, E., Sapienza, F.G., Ballanti, S., Mele, G., Galli, M., Pirrotta, M.T. & Di Raimondo, F. (2012) Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer, 118, 1574-1584.
17. Hallek, M., Bergsagel, P.L. & Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3-21.
18. Katodritoua, E., Gastari, V., Verrouab, E., Hadjiaggelidoua, C., Varthaliti, M., Georgiadoua, S., Laschos, K., Xirou, P., Yiannaki, E., Constantinou, N., Markala, D. & Zervas, K. (2009) Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leukemia Research, 33, 1137-1140.
19. Kremer, M., Ott, G., Nathrath, M., Specht, K., Stecker, K., Alexiou, C., Quintanilla-Martinez, L. & Fend, F. (2005) Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. Journal of Pathology, 205, 92-101.
20. Kröger, N., Schilling, G., Einsele, H., Liebisch, P., Shimoni, A., Nagler, A., Perez-Simon, J.A., San Miguel, J.F., Kiehl, M., Fauser, A., Schwerdtfeger, R., Wandt, H., Sayer, H.G., Myint, H., Klingemann, H., Zabelina, T., Dierlamm, J., Hinke, A. & Zander, A.R. (2004) Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood, 103, 4056-4061.
21. Kuehl, W.M. & Bergsagel, P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175-187.
22. López-Anglada, L., Gutiérrez, N.C., García, J.L., Mateos, M.V., Flores, T. & San Miguel, J.F. (2010) P53 may drive the clinical evolution and treatment response in multiple myeloma. European Journal of Haematology, 84, 359-361.
23. Minnema, M.C., van de Donk, N.W., Zweegman, S., Hegenbart, U., Schonland, S., Raymakers, R., Zijlmans, J.M., Kersten, M.J., Bos, G.M. & Lokhorst, H.M. (2008) Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplantation, 41, 779-784.
24. Nobuyoshi, M., Kawano, M., Tanaka, H., Ishikawa, H., Tanabe, O., Iwato, K., Asaoku, H., Sakai, A. & Kuramoto, A. (1991) Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. British Journal of Haematology, 77, 523-528.
25. Owen, R.G., Feyler, S., O' Connor, S.J.M., Bond, L.R., De Tute, R.M. & Rawstron, A.C. (2011) Defining IgM multiple myeloma. American Journal of Hematology, 86, 717.
26. Pabst, C., Zustin, J., Jacobsen, F., Luetkens, T., Kröger, N., Schilling, G., Bokemeyer, C., Sauter, G., Atanackovic, D. & Marx, A. (2010) Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Experimental Molecular Pathology, 89, 175-181.
27. Rasche, L., Bernard, C., Topp, M.S., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H. & Knop, S. (2012) Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Annals of Hematology, 91, 1031-1037.
28. Sawyer, J.R. (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genetics, 204, 3-12.
29. Schilling, G., Hansen, T., Shimoni, A., Zabelina, T., Simon-Perez, J.A., Gutierrez, N.C., Bethge, W., Liebisch, P., Schwerdtfeger, R., Bornhäuser, M., Otterstetter, S., Murga Penas, E.M., Dierlamm, J., Ayuk, F., Atanackovic, D., Bacher, U., Bokemeyer, C., Zander, A., San Miguel, J., Nagler, A. & Kröger, N. (2008) Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 22, 1250-1255.
30. Schuster, S.R., Rajkumar, S.V., Dispenzieri, A., Morice, W., Aspitia, A.L., Ansell, S., Kyle, R. & Mikhael, J. (2011) The definition of IgM multiple Myeloma. American Journal of Hematology, 86, 718-719.
31. Terpos, E., Rezvani, K., Basu, S., Milne, A.E., Rose, P.E. & Scott, G.L. (2005) Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology, 75, 376-383.
32. The International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
33. Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. & Lazzarino, M. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 21, 325-330.
34. Venables, W.N. & Ripley, B.D. (2002) Modern Applied Statistics with S, 4th edn. Springer, New York.
35. Zeiser, R., Deschler, B., Bertz, H., Finke, J. & Engelhardt, M. (2004) Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplantation, 34, 1057-1065.